Galmed Q2 Loss Widens to $2.7M; MVLS Falls Below Nasdaq's $5M Threshold
GLMD sits 25% above its 52-week low of $3.289 on light trading volume (0.1× avg).
Summary
Galmed reported a wider Q2 net loss of $2.7M and disclosed its market value has fallen below Nasdaq's $5M minimum listing threshold, adding delisting risk to an already cash-constrained biotech.
Key Events · Earnings and Guidance · GLMD
-
Q2 Net Loss Widens to $2.7M
Net loss for Q2 2026 was $2.7M vs $2.5M in Q2 2025; H1 2026 loss was $4.6M vs $3.6M. R&D expenses rose 82% YoY to $3.1M for H1, driven by clinical and pre-clinical trial costs.
-
MVLS Below Nasdaq $5M Threshold
As of September 1, 2026, Galmed's Market Value of Listed Securities was approximately $4.2M, below the $5.0M minimum under a new Nasdaq rule. The rule is currently stayed by the SEC, but if lifted, Galmed faces immediate delisting proceedings with no cure period.
-
Colospan Purchase Price Allocation Disclosed
Total consideration for Colospan was $4.9M ($3.3M cash + $1.6M contingent consideration). Allocation: $4.6M intangible assets (7-year life), $1.8M goodwill, $1.1M deferred tax liability.
-
Post-Quarter SEPA Issuance
After June 30, 2026, Galmed sold 40,957 ordinary shares under its SEPA facility for approximately $0.3M net proceeds, continuing dilutive equity financing.
Analysis · GLMD · Life Sciences
Galmed's Q2 2026 net loss widened to $2.7 million from $2.5 million a year earlier, with R&D spending up 64% as the company pivots to oncology and integrates the Colospan acquisition. More pressing is the disclosure that as of September 1, 2026, the company's Market Value of Listed Securities was approximately $4.2 million — below the $5.0 million minimum under a new Nasdaq rule that, while currently stayed by the SEC, could trigger immediate delisting proceedings if the stay is lifted. The company also disclosed it sold an additional 40,957 shares under its SEPA facility after quarter-end for roughly $0.3 million, continuing its reliance on dilutive equity financing.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GLMD was trading at $4.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $3.29 to $13.20. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.